ASH 2014: Phase I study shows that PD-1 inhibitor, nivolumab, is safe and tolerable in relapsed or refractory Hodgkin lymphoma

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Philippe Armand (Dana-Farber Cancer Institute, Boston, MA) discusses the results of a phase I study evaluating the preliminary efficacy and safety of programmed cell death 1 (PD-1) inhibitor, nivolumab, in patients with relapsed or refractory classical Hodgkin lymphoma.